ELAN SIGNS LICENSE AGREEMENT WITH ABBOTT FOR ELAN'S PROPRIETARY NANOCRYSTAL TECHNOLOGY

Elan Corporation, plc today announced that it has entered into a License Agreement with Abbott Pharmaceutical PR Ltd in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilize Elan' proprietary NanoCrystal Technology to develop and commercialize a single fixed-dose combination product containing the active pharmaceutical ingredients in Abbott's TriCor145 (fenofibrate) and AstraZeneca's Crestor (rosuvastatin calcium) products. Business Wire (http://home.businesswire.com/portal/site/home/?epi_menuItemID=989a6827590d7dda9cdf6023a0908a0c&epi_menuID=c791260db682611740b28e347a808a0c&epi_baseMenuID=384979e8cc48c441ef0130f5c6908a0c&ndmViewId=news_view&newsLang=en&div=1192646576&newsId=20060705005965)